Literature DB >> 21975748

Thiazide diuretics and the risk of hip fracture.

Koko Aung1, Thwe Htay.   

Abstract

BACKGROUND: Thiazide diuretics are one of the most commonly prescribed antihypertensive agents worldwide. Thiazides reduce urinary calcium excretion. Chronic ingestion of thiazides is associated with higher bone mineral density. It has been suggested that thiazides may prevent hip fracture. However, there are concerns that diuretics, by increasing the risk of fall in elderly, could potentially negate its beneficial effects on hip fracture.
OBJECTIVES: To assess any association between the use of thiazide diuretics and the risk of hip fracture in adults. SEARCH STRATEGY: We searched eligible studies up to December 2008 in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), the Cumulative Index to Nursing and Allied Health Literature (CINAHL), International Pharmaceutical Abstracts, the Database of Abstracts of Review of Effects (DARE) and reference lists of previous reviews and included studies. SELECTION CRITERIA: All randomized controlled trials and observational studies, which assessed the association between thiazide diuretic use and hip fracture. DATA COLLECTION AND ANALYSIS: Two review authors independently applied the selection criteria, extracted data and assessed risk of bias of each study selected.  The results were summarized descriptively and quantitatively. Cohort studies and case control studies were analysed separately. MAIN
RESULTS: No randomized control trials were found. Twenty-one observational studies with nearly four hundred thousand participants were included. Six of them were cohort studies and 15 were case-control studies. Two cohort studies appear to involve the same cohort so there were only 5 unique ones. The risk of bias was assessed with the Newcastle-Ottawa Scale (NOS). Five cohort studies had low risk of bias and one had moderate risk of bias. Seven case control studies had low risk of bias and 8 had moderate risk of bias. Meta-analysis of cohort studies showed that thiazide use was associated with a reduction in risk of hip fracture by 24%, pooled RR 0.76 (95% CI 0.64-0.89; p = 0.0009). We chose not to provide a pooled summary statistics for case-control studies because of high heterogeneity (Tau(2) = 0.03, I(2) = 62%, p = 0.0008). AUTHORS'
CONCLUSIONS: Thiazides appear to reduce the risk of hip fracture based on observational studies. Randomized controlled trials are needed to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21975748     DOI: 10.1002/14651858.CD005185.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  35 in total

Review 1.  The effects of fall-risk-increasing drugs on postural control: a literature review.

Authors:  Maartje H de Groot; Jos P C M van Campen; Marije A Moek; Linda R Tulner; Jos H Beijnen; Claudine J C Lamoth
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

2.  Antihypertensive medication and risk of kidney stones: a Canadian wake-up call.

Authors:  Daniel G Fuster
Journal:  Hypertens Res       Date:  2017-04-06       Impact factor: 3.872

3.  Response to: A role for thiazide diuretic therapy in preventing bone loss, fracture and nephrolithiasis in individuals with thalassemia and hypercalciuria?

Authors:  A D Dede; G Trovas; E Chronopoulos; I K Triantafyllopoulos; I Dontas; N Papaioannou; S Tournis
Journal:  Osteoporos Int       Date:  2017-02-13       Impact factor: 4.507

4.  The ageing endocrine system: Fracture risk after initiation of antihypertensive therapy.

Authors:  Lars Rejnmark
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

5.  Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades.

Authors:  Marcio L Griebeler; Ann E Kearns; Euijung Ryu; Prabin Thapa; Matthew A Hathcock; L Joseph Melton; Robert A Wermers
Journal:  J Clin Endocrinol Metab       Date:  2016-01-11       Impact factor: 5.958

6.  Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial.

Authors:  Karen L Margolis; Lisa Palermo; Eric Vittinghoff; Gregory W Evans; Hal H Atkinson; Bruce P Hamilton; Robert G Josse; Patrick J O'Connor; Debra L Simmons; Margaret Tiktin; Ann V Schwartz
Journal:  J Gen Intern Med       Date:  2014-08-16       Impact factor: 5.128

Review 7.  Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis.

Authors:  Mahua Ghosh; Sumit R Majumdar
Journal:  Endocrine       Date:  2014-02-07       Impact factor: 3.633

Review 8.  The Impact of Antihypertensive Medications on Bone Mineral Density and Fracture Risk.

Authors:  Joshua I Barzilay; Barry R Davis; Sara L Pressel; Alokananda Ghosh; Rachel Puttnam; Karen L Margolis; Paul K Whelton
Journal:  Curr Cardiol Rep       Date:  2017-09       Impact factor: 2.931

9.  Optimal age of commencing and discontinuing thiazide therapy to protect against fractures.

Authors:  C Kruse; P Eiken; P Vestergaard
Journal:  Osteoporos Int       Date:  2015-12-11       Impact factor: 4.507

Review 10.  Idiopathic hypercalciuria and formation of calcium renal stones.

Authors:  Fredric L Coe; Elaine M Worcester; Andrew P Evan
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.